Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10719321 | 0.92 | TSHR (0.43) | TSHRDNM1ALDH1A1ADH1BADH1C | |
| SCHEMBL17073505 | 0.90 | DNM1 (0.50) | TSHRDNM1CA1CA2CA12 | |
| SCHEMBL2886639 | 0.90 | DNM1 (0.36) | TSHRDNM1CA1CA12ALDH1A1 | |
| SCHEMBL2883930 | 0.90 | TSHR (0.38) | TSHRDNM1CA1CA2CA12 | |
| SCHEMBL21016410 | 0.87 | DNM1 (0.46) | TSHRDNM1ALDH1A1ADH1BADH1C | |
| SCHEMBL27890407 | 0.85 | DNM1 (0.50) | TSHRDNM1ALDH1A1ADH1BADH1C | |
| SCHEMBL5699101 | 0.83 | ALDH1A1 (0.38) | TSHRDNM1CA1CA12ALDH1A1 | |
| SCHEMBL2852729 | 0.82 | DNM1 (0.46) | TSHRDNM1CA1CA2CA12 | |
| SCHEMBL2886173 | 0.81 | — | — | |
| SCHEMBL2885824 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210383321-A1 | VEHICLE FLEET CONTROL SYSTEMS AND METHODS | RYDER INTEGRATED LOGISTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-10179775-B2 | Cyclooctenes for bioorthogonol reactions | THE GENERAL HOSPITAL CORPORATION (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170233365-A1 | CYCLOOCTENES FOR BIOORTHOGONOL REACTIONS | THE GENERAL HOSPITAL CORPORATION | 2017-08-17 | — | — | US | disclosed |
| US-7670753-B2 | Lithographic printing plate precursor | EASTMAN KODAK COMPANY (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080261146-A1 | Lithographic Printing Plate Precursor | EASTMAN KODAK COMPANY | 2008-10-23 | — | — | US | disclosed |
| EP-1782127-B1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR | EASTMAN KODAK CO (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1782127-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR | EASTMAN KODAK COMPANY (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006023667-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR | EASTMAN KODAK COMPANY (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179775-B2 | Cyclooctenes for bioorthogonol reactions | SQLE, BBOX1, TKT | TSHR 2511/4885DNM1 1652/4885CA1 3511/4885 |
| US-20170233365-A1 | CYCLOOCTENES FOR BIOORTHOGONOL REACTIONS | SQLE, BBOX1, TKT | TSHR 2511/4885DNM1 1652/4885CA1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.